Funabashi, Japan

Yuki Kuwano

This inventor holds 1 USPTO granted patent. Top assignees: Nissan Chemical Corporation, Shionogi & Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuki Kuwano. Retrieved from https://idiyas.com/inventor/yuki-kuwano-uysk2jg1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 1.0


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuki Kuwano: Pharmaceutical Chemistry Inventor

Introduction

Yuki Kuwano is an inventor associated with pharmaceutical research and patent activity in Japan. The supplied information identifies her as a woman based in Funabashi, Japan, and credits her with 1 patent.

Latest Patents

Kuwano is named on the patent “Substituted pyrazolo[1,5-a]pyrimidines as sepiapterin reductase inhibitors.” The invention concerns condensed heterocyclic compounds that inhibit sepiapterin reductase and may be useful in treating pain. The patent also describes tautomers, pharmaceutically acceptable salts, and solvates of the compounds.

Career Highlights

The provided career information associates Kuwano with Nissan Chemical Corporation and Shionogi & Co., Ltd. Her patent reflects work involving medicinal chemistry and the development of compounds with potential therapeutic applications.

Collaborations

Masahiro Kamaura and Yusuke Inaba are identified as Kuwano’s coworkers. Their names are also associated with the patent information provided.

Conclusion

Yuki Kuwano’s recorded patent focuses on sepiapterin reductase inhibitors and their potential use in pain treatment, highlighting her connection to pharmaceutical innovation in Japan.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…